Company: TYRA
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0000950170-25-046124
Chunk: 261

Company: Tyra Biosciences, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 261
---
(1)

        30,423

        20,039

              Facilities and other costs(2)

        6,113

        4,253

        Total research and development expenses

        80,077

        62,518

        General and administrative expenses(3)

        24,100

        17,427

        Interest and other income, net

        (17,696
        )

        (10,811
        )

        Net loss
         
        $
        (86,481
        )
         
        $
        (69,134
        )
       
      (1) Personnel costs include $14.3 million and $8.3 million of stock-based compensation for the years ended December 31, 2024 and 2023, respectively.(2) Facilities and other costs consist of research consumables, facility-related costs, depreciation and costs not attributed to a specific program.(3) General and administrative expenses consist of personnel-related expenses, including stock-based compensation, legal fees, facility-related costs, depreciation, professional and consulting fees and insurance costs.

14. Subsequent EventsSubsequent to December 31, 2024, Exchange Warrants (as defined in Note 6) to purchase an aggregate of 2,000,000 shares of common stock and 2024 Pre-Funded Warrants (as defined in Note 6) to purchase 237 shares of common stock were exercised in cashless transactions, which resulted in an aggregate of 2,000,069 shares of common stock being issued.Effective January 1, 2025, the Company amended its 401(k) Plan to adopt a program to match 100% of employee contributions to the 401(k) Plan up to a maximum of 4% of eligible earnings, subject to statutory limitations.

137